Medpace Holdings, Inc. Operating Lease Cost
Medpace Holdings, Inc. (MEDP) reported Operating Lease Cost of $8.04 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-07-23
- Medpace Holdings, Inc. operating lease, cost for the quarter ending 2026-06-30 was $8.04M, a 4.59% increase year-over-year.
- Medpace Holdings, Inc. operating lease, cost for the quarter ending 2026-03-31 was $7.74M, a 4.00% decline year-over-year.
- Medpace Holdings, Inc. operating lease, cost for the quarter ending 2025-12-31 was $7.63M, a 2.97% decline year-over-year.
- Medpace Holdings, Inc. operating lease, cost for the quarter ending 2025-09-30 was $7.67M, a 3.61% decline year-over-year.
- Medpace Holdings, Inc. operating lease, cost for fiscal 2025 was $31.06M, a 1.70% decline from fiscal 2024.
- Medpace Holdings, Inc. operating lease, cost for fiscal 2024 was $31.59M, a 13.16% increase from fiscal 2023.
- Medpace Holdings, Inc. operating lease, cost for fiscal 2023 was $27.92M, a 7.90% increase from fiscal 2022.
- Medpace Holdings, Inc. operating lease, cost for fiscal 2022 was $25.87M, a 8.38% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.04M 10-Q · filed 2026-07-23 | $15.78M 10-Q · filed 2026-07-23 | $23.41M derived: sum of 3 quarters · filed 2026-07-23 | $31.09M derived: sum of 4 quarters · filed 2026-07-23 |
| 2026-03-31 | $7.74M 10-Q · filed 2026-04-23 | $15.37M derived: sum of 2 quarters · filed 2026-04-23 | $23.05M derived: sum of 3 quarters · filed 2026-04-23 | $30.73M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-12-31 | $7.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $15.30M derived: sum of 2 quarters · filed 2026-02-10 | $22.99M derived: sum of 3 quarters · filed 2026-07-23 | $31.06M 10-K · filed 2026-02-10 |
| 2025-09-30 | $7.67M 10-Q · filed 2025-10-23 | $15.36M derived: sum of 2 quarters · filed 2026-07-23 | $23.43M 10-Q · filed 2025-10-23 | $31.29M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-06-30 | $7.69M 10-Q · filed 2026-07-23 | $15.75M 10-Q · filed 2026-07-23 | $23.62M derived: sum of 3 quarters · filed 2026-07-23 | $31.58M derived: sum of 4 quarters · filed 2026-07-23 |
| 2025-03-31 | $8.06M 10-Q · filed 2026-04-23 | $15.93M derived: sum of 2 quarters · filed 2026-04-23 | $23.89M derived: sum of 3 quarters · filed 2026-04-23 | $31.79M derived: sum of 4 quarters · filed 2026-04-23 |
| 2024-12-31 | $7.87M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $15.82M derived: sum of 2 quarters · filed 2026-02-10 | $23.73M derived: sum of 3 quarters · filed 2026-02-10 | $31.59M 10-K · filed 2026-02-10 |
| 2024-09-30 | $7.96M 10-Q · filed 2025-10-23 | $15.86M derived: sum of 2 quarters · filed 2025-10-23 | $23.73M 10-Q · filed 2025-10-23 | $31.01M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-06-30 | $7.90M 10-Q · filed 2025-07-22 | $15.77M 10-Q · filed 2025-07-22 | $23.05M derived: sum of 3 quarters · filed 2026-02-10 | $30.05M derived: sum of 4 quarters · filed 2026-02-10 |
| 2024-03-31 | $7.87M 10-Q · filed 2025-04-22 | $15.15M derived: sum of 2 quarters · filed 2026-02-10 | $22.15M derived: sum of 3 quarters · filed 2026-02-10 | $29.10M derived: sum of 4 quarters · filed 2026-02-10 |
| 2023-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-10 | $14.28M derived: sum of 2 quarters · filed 2026-02-10 | $21.24M derived: sum of 3 quarters · filed 2026-02-10 | $27.92M 10-K · filed 2026-02-10 |
| 2023-09-30 | $7.00M 10-Q · filed 2024-10-22 | $13.96M derived: sum of 2 quarters · filed 2024-10-22 | $20.64M 10-Q · filed 2024-10-22 | $27.15M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-06-30 | $6.95M 10-Q · filed 2024-07-23 | $13.63M 10-Q · filed 2024-07-23 | $20.15M derived: sum of 3 quarters · filed 2025-02-11 | $26.63M derived: sum of 4 quarters · filed 2025-02-11 |
| 2023-03-31 | $6.68M 10-Q · filed 2024-04-23 | $13.20M derived: sum of 2 quarters · filed 2025-02-11 | $19.68M derived: sum of 3 quarters · filed 2025-02-11 | $26.05M derived: sum of 4 quarters · filed 2025-02-11 |
| 2022-12-31 | $6.52M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-11 | $13.00M derived: sum of 2 quarters · filed 2025-02-11 | $19.37M derived: sum of 3 quarters · filed 2025-02-11 | $25.87M 10-K · filed 2025-02-11 |
| 2022-09-30 | $6.48M 10-Q · filed 2023-10-24 | $12.86M derived: sum of 2 quarters · filed 2023-10-24 | $19.36M 10-Q · filed 2023-10-24 | $25.74M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-06-30 | $6.38M 10-Q · filed 2023-07-25 | $12.88M 10-Q · filed 2023-07-25 | $19.26M derived: sum of 3 quarters · filed 2024-02-13 | $25.20M derived: sum of 4 quarters · filed 2024-02-13 |
| 2022-03-31 | $6.50M 10-Q · filed 2023-04-25 | $12.88M derived: sum of 2 quarters · filed 2024-02-13 | $18.83M derived: sum of 3 quarters · filed 2024-02-13 | $24.64M derived: sum of 4 quarters · filed 2024-02-13 |
| 2021-12-31 | $6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-13 | $12.33M derived: sum of 2 quarters · filed 2024-02-13 | $18.14M derived: sum of 3 quarters · filed 2024-02-13 | $23.87M 10-K · filed 2024-02-13 |
| 2021-09-30 | $5.94M 10-Q · filed 2022-10-25 | $11.76M derived: sum of 2 quarters · filed 2022-10-25 | $17.49M 10-Q · filed 2022-10-25 | $23.18M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $5.82M 10-Q · filed 2022-07-26 | $11.55M 10-Q · filed 2022-07-26 | $17.24M derived: sum of 3 quarters · filed 2023-02-14 | $22.75M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $5.73M 10-Q · filed 2022-04-26 | $11.42M derived: sum of 2 quarters · filed 2023-02-14 | $16.93M derived: sum of 3 quarters · filed 2023-02-14 | $21.80M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $5.69M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $11.20M derived: sum of 2 quarters · filed 2023-02-14 | $16.07M derived: sum of 3 quarters · filed 2023-02-14 | $19.84M 10-K · filed 2023-02-14 |
| 2020-09-30 | $5.51M 10-Q · filed 2021-10-26 | $10.38M derived: sum of 2 quarters · filed 2021-10-26 | $14.15M 10-Q · filed 2021-10-26 | $17.73M derived: sum of 4 quarters · filed 2021-10-26 |
| 2020-06-30 | $4.87M 10-Q · filed 2021-07-27 | $8.64M 10-Q · filed 2021-07-27 | $12.21M derived: sum of 3 quarters · filed 2021-07-27 | $15.45M derived: sum of 4 quarters · filed 2021-07-27 |
| 2020-03-31 | $3.77M 10-Q · filed 2021-04-27 | $7.34M derived: sum of 2 quarters · filed 2021-04-27 | $10.58M derived: sum of 3 quarters · filed 2021-04-27 | $13.80M derived: sum of 4 quarters · filed 2021-04-27 |
| 2019-12-31 | $3.57M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-16 | $6.81M derived: sum of 2 quarters · filed 2021-02-16 | $10.03M derived: sum of 3 quarters · filed 2021-02-16 | $13.15M 10-K · filed 2021-02-16 |
| 2019-09-30 | $3.24M 10-Q · filed 2020-10-27 | $6.46M derived: sum of 2 quarters · filed 2020-10-27 | $9.58M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $3.22M 10-Q · filed 2020-07-28 | $6.34M 10-Q · filed 2020-07-28 | ||
| 2019-03-31 | $3.12M 10-Q · filed 2020-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |